News & Views
Research Focused on CNS Disease
Jan 08 2019
Domain Therapeutics (Strasbourg) and Boehringer Ingelheim are collaborating in a multi-target drug discovery and licensing agreement on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.
Domain Therapeutics will use its proprietary platforms, DTect-All™ and bioSens-All™, which enable characterisation of small molecule GPCR binders for the screening of potential lead compounds. Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details were not disclosed.
“We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts,” said Dr Bernd Sommer, Global Head, CNS Diseases Research at Boehringer Ingelheim. “We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”
“With its focus on emerging science and breakthrough medicines, we are enthusiastic to be working with Boehringer Ingelheim,” said Pascal Neuville, CEO of Domain Therapeutics. “We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets and coupled with Boehringer Ingelheim’s strength and expertise, their rapid advancement into the clinic.”
Digital Edition
Lab Asia 31.6 Dec 2024
December 2024
Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...
View all digital editions
Events
Jan 22 2025 Tokyo, Japan
Jan 22 2025 Birmingham, UK
Jan 25 2025 San Diego, CA, USA
Jan 27 2025 Dubai, UAE
Jan 29 2025 Tokyo, Japan